Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for the treatment of cancer.
Headquartered in San Diego, California, Kura Oncology specializes in targeted therapies that aim to inhibit the molecular drivers of cancer, providing more effective and less toxic treatment options for patients. The company’s lead programs are focused on cancers driven by specific genetic mutations, including HRAS, KRAS, and other oncogenes.
Kura’s flagship drug candidate, tipifarnib, is being developed for the treatment of head and neck squamous cell carcinoma (HNSCC) and other solid tumors. The company’s growth is driven by its robust pipeline of targeted therapies, strategic partnerships, and a strong focus on precision oncology. By leveraging advances in genomics and molecular biology,
Kura Oncology is positioned to make significant contributions to the evolving landscape of cancer treatment, offering hope for improved outcomes in patients with hard-to-treat cancers.
